查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717097

老龄化黄斑部病变市场：2025-2030 年全球预测（按类型、治疗方法、交付方式、医疗环境和分销管道）

Age-related Macular Degeneration Market by Type, Treatment Modality, Delivery Method, Healthcare Setting, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年老龄化黄斑部病变市场价值将达到104.5亿美元，2024年将成长至111亿美元，复合年增长率为6.67%，到2030年将达到164.3亿美元。

主要市场统计数据
基准年2023年 104.5亿美元
预计年份：2024年 111亿美元
预测年份 2030 164.3亿美元
复合年增长率（%） 6.67%

老龄化黄斑部病变(AMD) 已成为医疗保健专业人员、研究人员和医疗保健行业决策者日益关注的重点。这种进行性眼科疾病仍然是全球老年人视力丧失的主要原因。最近的治疗方法进展、新技术和正在进行的流行病学研究正在扩大我们对 AMD 的理解。在如此复杂的环境中，准确评估治疗方案、护理管道以及各种区域动态的影响对于制定未来策略至关重要。

这项分析全面审视了 AMD 的多面性，并将讨论扩展到了传统临床观点之外。探索影响市场的关键驱动因素，考虑关键细分标准，并揭示最新治疗性介入背后不断发展的治疗方法。讨论旨在帮助决策者更好地了解 AMD 生态系统中存在的挑战和潜在机会。随着临床测试和监管核准在治疗领域不断取得新突破，相关人员被鼓励考虑其职责范围内的短期和长期影响。

后续章节深入分析了治疗领域的动态变化、类型、治疗方式、交付方式、医疗环境和分销管道的详细细分，并深入探讨了影响这些趋势的地区和企业因素。解开这些因素可以提供专家级的说明，以帮助 AMD 管理层进行策略规划和创新机会。

改变老龄化黄斑部病变市场

老龄化黄斑部病变的治疗前景正在发生巨大变化，反映了医学的快速进步和患者需求的变化。在技​​术突破和先进的临床方法的推动下，该行业正在经历从传统治疗方法转向更有针对性和个性化的方法的转变。这种转变的特点是药物和外科手术介入的创新。

不断发展的治疗策略包括开发新型抗发炎和抗 VEGF 药物、创新抗氧化剂和补充剂配方以及新兴基因疗法。这些治疗方法极大地改变了患者的治疗效果，尤其是在分子生物学和药物传递技术的突破下。同时，雷射治疗、黄斑转位术、动态疗法和先进的玻璃体切除手术等精准手术介入技术也不断发展。这两种介入方法都旨在降低手术相关风险并改善 AMD 患者的长期功能结果。

此外，采用数位健康解决方案进行远端监控和更及时的干预进一步凸显了产业的不断变化。这种转变不仅会影响临床结果，还将推动市场需求和主要相关人员策略重点的转变。研究、监管变化和以患者为中心的创新之间的相互作用促使行业资深人士重新思考既定的范式，并适应以动态、以患者为中心的干预措施成为未来常态的环境。

AMD 市场关键细分洞察

为了更了解AMD市场，需要进行多方面的细分。当考虑疾病类型时，市场分为两大类：干性老龄化黄斑部病变和湿性老龄化黄斑部病变。盛行率和治疗反应的差异需要对这些亚型进行详细比较。

除了基于类型的基本区分之外，市场还根据治疗方法进一步细分。主要治疗方法分为药物治疗和手术介入。製药部门本身涵盖频谱子类别，例如抗发炎药物、抗 VEGF 药物、抗氧化剂和补充剂、基因疗法等，每种药物都有其独特的作用机制和临床影响。相较之下，手术介入的特点是成熟和新兴的方法，例如雷射治疗、黄斑转位术、动态疗法和玻璃体切除术。这些介入措施已经改进，可以改善患者的治疗效果，同时最大限度地降低风险。

此外，治疗可以透过注射、玻璃体内注射或口服进行。这些治疗的实施环境进一步分化了市场。医疗保健环境多种多样，包括门诊手术中心、专科医院和专科眼科诊所。最后，促进这些治疗方法应用的通路（如医院药局、网路药局和零售药局）进一步分化了市场。这种全面的细分对于了解市场动态至关重要，并有助于相关人员自订他们的方案来满足治疗过程中每个阶段患者的特定需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球老龄人口不断增加
      • 雷射治疗和抗血管新生药物的使用迅速增加
      • 不断增加诊断设施和技术，以有效侦测AMD
    • 限制因素
      • AMD相关药物召回的潜在风险
    • 机会
      • 政府对 AMD 的重要措施和资金支持
      • 透过细胞疗法和组织工程引入新的先进治疗方法
    • 任务
      • 严格的法规环境和复杂的新治疗方法核准
  • 市场区隔分析
    • 类型：针对干性AMD患者视力逐渐丧失且快速丧失的情况，进行个人化治疗
    • 治疗方法：老龄化黄斑部病变的综合管理和创新药物治疗
    • 给药方法：针对老龄化黄斑部病变的创新註射方法
    • 医疗保健环境：透过 ASC、医院和诊所提供先进、经济高效的治疗，为 AMD 管理提供全面的护理
    • 分销管道：分销AMD治疗药物的线上药局的激增将确保全面的患者照护
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境
  • 客户客製化
    • 接受政府治疗的患者人数和平均治疗费用

第六章老龄化黄斑部病变市场（按类型）

  • 介绍
  • 干性老龄化黄斑部病变
  • 湿性老龄化黄斑部病变

第七章老龄化黄斑部病变市场（依治疗方法）

  • 介绍
  • 製药
    • 抗发炎药物
    • 抗VEGF药物
    • 抗氧化剂和补充剂
    • 基因治疗
  • 手术介入
    • 雷射治疗
    • 黄斑移位手术
    • 动态疗法
    • 玻璃体切除手术

第八章老龄化黄斑部病变市场（依管理法）

  • 介绍
  • 注射
  • 玻璃体内植入
  • 口服

老龄化黄斑部病变市场（依医疗环境）

  • 介绍
  • 门诊手术中心
  • 医院
  • 眼科诊所

老龄化黄斑部病变市场（依分销管道）

  • 介绍
  • 医院药房
  • 网路药局
  • 零售药局

第 11 章。美洲老龄化黄斑部病变市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区老龄化黄斑部病变市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 13 章。欧洲、中东和非洲的老龄化黄斑部病变市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2023年市场占有率分析
  • 2023年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • Adverum BIoTechnologies, Inc.
  • Alkeus Pharmaceuticals, Inc.
  • Allegro Ophthalmics, LLC
  • Amgen Inc.
  • Annexon, Inc.
  • Apellis Pharmaceuticals, Inc.
  • AsclepiX Therapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Biocon Ltd
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • EyePoint Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Formycon AG
  • Grifols, SA
  • Ionis Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Kodiak Sciences Inc.
  • Lineage Cell Therapeutics, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • PanOptica, Inc.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sandoz Group AG
  • Sun Pharmaceutical Industries, Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-F927BA46233D

The Age-related Macular Degeneration Market was valued at USD 10.45 billion in 2023 and is projected to grow to USD 11.10 billion in 2024, with a CAGR of 6.67%, reaching USD 16.43 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 10.45 billion
Estimated Year [2024] USD 11.10 billion
Forecast Year [2030] USD 16.43 billion
CAGR (%) 6.67%

Age-related Macular Degeneration (AMD) has increasingly become a central focus for medical practitioners, researchers, and decision-makers across the healthcare industry. This progressive eye condition remains a leading cause of vision loss in older adults worldwide. Recent advancements in treatment methods, emerging technologies, and ongoing epidemiological research have expanded our understanding of AMD. In this complex environment, accurately evaluating treatment options, care delivery channels, and the influence of various regional dynamics is critical to shaping future strategies.

This analysis takes a comprehensive look into the multifaceted world of AMD, where discussions extend beyond the traditional clinical perspectives. It explores key drivers affecting the market, reviews important segmentation criteria, and provides clarity on the evolving treatment modalities that underpin modern therapeutic interventions. The discussion here is designed to offer decision-makers a refined understanding of the challenges and potential opportunities that lie in the AMD ecosystem. As clinical trials and regulatory approvals steadily open up new horizons in treatment, stakeholders are encouraged to consider both immediate and long-term implications for their respective spheres of responsibility.

The subsequent sections delve into dynamic shifts in treatment landscapes, granular segmentation insights including type, treatment modality, delivery method, healthcare setting, and distribution channel, as well as the regional and corporate contributors shaping these trends. By unpacking these elements, this overview offers an expert-level narrative designed to inform strategic planning and potential areas for innovation in managing AMD.

Transformative Shifts in AMD Treatment Landscape

The treatment landscape for Age-related Macular Degeneration has experienced dramatic changes, reflecting rapid advancements in medical science and evolving patient needs. Driven by technological breakthroughs and refined clinical approaches, the industry is witnessing a shift from traditional treatment methods to more targeted and personalized approaches. This transformation is characterized by innovations in both pharmaceuticals and surgical interventions.

The evolution in treatment strategies includes the development of novel Anti-inflammatory Drugs, Anti-VEGF Agents, innovative Antioxidants & Supplements formulations, and emerging Gene Therapy Drugs. These therapies, especially in light of breakthroughs in molecular biology and drug delivery techniques, have significantly altered the prognosis for patients. Simultaneously, surgical interventions have evolved with precision-based procedures such as Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and advanced Vitrectomy techniques. Each of these intervention approaches is designed to reduce the procedure-related risks and enhance the long-term functional outcomes for those affected by AMD.

Moreover, the adoption of digital health solutions for remote monitoring and more timely interventions further underscores an industry in flux. This transformative shift not only influences clinical outcomes but also drives changes in market demand and strategic priorities among key stakeholders. The interplay of research, regulatory changes, and patient-centric innovations is prompting industry veterans to rethink established paradigms and adapt to an environment where dynamic, patient-focused interventions are the future norm.

Critical Segmentation Insights in the AMD Market

A nuanced understanding of the AMD market requires dissecting its segmentation across multiple dimensions. When considering disease type, the market accommodates two central categories: Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration. The differential prevalence and the variation in therapeutic responsiveness necessitate a detailed comparison of these subtypes.

Beyond the fundamental differentiation by type, the market is further segmented based on treatment modality. Primarily, these therapeutic approaches fall into pharmaceuticals and surgical interventions. The pharmaceutical segment itself encompasses a spectrum of sub-categories including Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs, each with its own distinct mechanism of action and clinical impact. In contrast, surgical interventions are characterized by established and emerging procedures such as Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy. These interventions have been refined to enhance patient outcomes while minimizing risks.

In addition, delivery methods play a critical role in segmentation, with therapeutic agents being administered through injectable methods, intravitreal implants, or oral routes. The context within which these treatments are delivered further segments the market; healthcare settings vary from Ambulatory Surgical Centers to dedicated Hospitals and specialized Ophthalmology Clinics. Lastly, the distribution channels that facilitate the reach of these treatments-whether through Hospital Pharmacies, Online Pharmacies, or Retail Pharmacies-add yet another layer of detail. Such comprehensive segmentation is essential to understanding market dynamics and assists stakeholders in tailoring their approaches to address the specific needs at every step of the patient care continuum.

Based on Type, market is studied across Dry Age-Related Macular Degeneration and Wet Age-Related Macular Degeneration.

Based on Treatment Modality, market is studied across Pharmaceuticals and Surgical Interventions. The Pharmaceuticals is further studied across Anti-inflammatory Drugs, Anti-VEGF Agents, Antioxidants & Supplements, and Gene Therapy Drugs. The Surgical Interventions is further studied across Laser Therapy, Macular Translocation Surgery, Photodynamic Therapy, and Vitrectomy.

Based on Delivery Method, market is studied across Injectable, Intravitreal implants, and Oral.

Based on Healthcare Setting, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmology Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Regional Insights Shaping AMD Market Trends

Regional dynamics play an influential role in the evolution of the AMD market, as variations in demographics, economic development, and healthcare infrastructure across different regions profoundly affect both access and treatment outcomes. In the Americas, robust healthcare systems and significant investment in research and development have spurred the early adoption of new technologies. This region's emphasis on advanced diagnostic techniques and personalized treatments is driving market growth and setting benchmarks for clinical innovation.

At the same time, the combined regions of Europe, the Middle East, and Africa showcase a diverse array of market conditions. Europe benefits from traditionally strong pharmaceutical research and a steady market for advanced therapies whereas both the Middle East and Africa are increasingly embracing modern healthcare practices. Despite the disparities in resource allocation, these regions are progressively adopting new treatment methodologies and integrating innovative supply chain solutions to improve access to care for AMD patients.

In Asia-Pacific, rapid economic development coupled with a rising elderly population has created a fertile ground for market expansion. The region is notable for its increasing investments in healthcare infrastructure and concerted efforts toward the adoption of cutting-edge diagnostic and treatment modalities. Emphasis on scalable, cost-effective solutions and robust public-private partnerships further propels the growth trajectory within these emerging markets. Collectively, these regional insights underscore the importance of geographic diversity in the strategic planning of AMD interventions and signal distinct opportunities for tailored market approaches.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights Driving Innovation in AMD Solutions

The AMD market is influenced by a cadre of leading companies whose innovations and strategic developments are shaping treatment paradigms. Notable industry pioneers such as AbbVie Inc. and Adverum Biotechnologies, Inc. have been trailblazers in advancing biopharmaceutical applications, playing a critical role in the promotion of next-generation therapies. Equally important are firms like Alkeus Pharmaceuticals, Inc. and Allegro Ophthalmics, LLC, whose research in novel drug formulations and surgical protocols have redefined the standards of care.

Other key players including Amgen Inc. and Annexon, Inc. have contributed significantly to the evolution of treatment efficacy and patient safety. Apellis Pharmaceuticals, Inc. and AsclepiX Therapeutics bring fresh perspectives to the market through progressive clinical developments, while Astellas Pharma Inc. and Bausch Health Companies Inc. provide vital market stability with their established portfolios. Bayer AG and Biocon Ltd further complement this ecosystem by driving collaborative research initiatives that bridge the gap between clinical research and practical application.

In addition, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., and F. Hoffmann-La Roche Ltd. are at the forefront of integrating technological advancements in treatment delivery. The insights provided by companies such as Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., and Johnson & Johnson Services, Inc. highlight the continuous interplay of innovation and clinical utility. Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., and Lupin Limited position themselves as early adopters of transformational treatment modalities, while industry leaders like Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. round out a comprehensive list of pioneers driving forward the future of AMD treatments. These companies not only lead in research and development but also actively shape market dynamics through strategic alliances and continuous innovation.

The report delves into recent significant developments in the Age-related Macular Degeneration Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adverum Biotechnologies, Inc., Alkeus Pharmaceuticals, Inc., Allegro Ophthalmics, LLC, Amgen Inc., Annexon, Inc., Apellis Pharmaceuticals, Inc., AsclepiX Therapeutics, Astellas Pharma Inc., Bausch Health Companies Inc., Bayer AG, Biocon Ltd, Biogen Inc., Clearside Biomedical, Inc., EyePoint Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formycon AG, Grifols, S.A., Ionis Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Kodiak Sciences Inc., Lineage Cell Therapeutics, Inc., Lupin Limited, Merck & Co., Inc., Nicox S.A., Novartis AG, PanOptica, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sandoz Group AG, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to capitalize on emerging technological innovations and evolving market dynamics to maintain a competitive edge. Evaluating the potential of next-generation therapeutics and novel drug delivery systems is paramount to driving improved patient outcomes. Decision-makers should prioritize research investments in both pharmaceutical and surgical domains, particularly in areas that promise reduced adverse effects and enhanced efficacy.

Leaders must also consider expanding healthcare infrastructure by integrating multi-channel distribution strategies. By bridging gaps between hospitals, ambulatory centers, and online platforms, stakeholders can ensure improved access to advanced treatment modalities. Strategic collaborations among research institutions, private enterprises, and regulatory bodies will be essential to facilitate faster adoption of breakthroughs. Tactical market segmentation analysis - including disease subtypes, treatment methods, and regional specifics - plays a critical role in identifying gaps and untapped opportunities. A proactive approach that blends investment in innovation with adaptive operational strategies will enable organizations to respond more effectively to the evolving landscape and better serve patients in a competitive market.

Conclusion and Future Outlook in AMD

The comprehensive review of the Age-related Macular Degeneration market reveals a dynamic environment marked by robust innovations, significant geographical variances, and an evolving list of key players. As transformative shifts in both pharmaceutical and surgical treatments redefine traditional practices, the opportunity for breakthroughs is more imminent than ever. The layered segmentation, spanning disease type, modality, administration method, healthcare setting, and distribution channels, provides valuable insights that can inform targeted strategic initiatives.

This analysis underscores the necessity for a forward-thinking approach that integrates technological advancements with strategic operational planning. Looking ahead, continued progress in the development of patient-centric therapies, heightened awareness across regional markets, and collaborative innovation among industry leaders hold the promise of enhanced outcomes for AMD patients. The future within this sector is promising, with the sustained potential for improved diagnostic and treatment options, which collectively pave the way for a more accessible and effective healthcare ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing number of geriatric population across the world
      • 5.1.1.2. Surging use of laser therapy and anti-angiogenesis drugs
      • 5.1.1.3. Increasing diagnostics facilities and technology for effective detection of AMD
    • 5.1.2. Restraints
      • 5.1.2.1. Potential risk of drug recalls associated with AMD
    • 5.1.3. Opportunities
      • 5.1.3.1. Significant government policies & funding for AMD
      • 5.1.3.2. Introduction of novel and advanced treatments based on cell therapy and tissue engineering
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory environment and complex approval of new treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Targeting gradual vision loss in dry AMD and rapid impairment with tailored treatments
    • 5.2.2. Treatment: Comprehensive management and innovative pharmaceutical treatments in age-related macular degeneration
    • 5.2.3. Delivery Method: Innovative injectable methods for age-related macular degeneration
    • 5.2.4. Healthcare Setting: Comprehensive care in AMD management through ASCs, hospitals, and clinics with advanced and cost-effective treatments
    • 5.2.5. Distribution Channel: Proliferation of online pharmacies for distributing AMD drugs to ensure comprehensive patient care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization
    • 5.5.1. Number of Patients Undergoing Treatments and Average Cost of Treatment By Country

6. Age-related Macular Degeneration Market, by Type

  • 6.1. Introduction
  • 6.2. Dry Age-Related Macular Degeneration
  • 6.3. Wet Age-Related Macular Degeneration

7. Age-related Macular Degeneration Market, by Treatment Modality

  • 7.1. Introduction
  • 7.2. Pharmaceuticals
    • 7.2.1. Anti-inflammatory Drugs
    • 7.2.2. Anti-VEGF Agents
    • 7.2.3. Antioxidants & Supplements
    • 7.2.4. Gene Therapy Drugs
  • 7.3. Surgical Interventions
    • 7.3.1. Laser Therapy
    • 7.3.2. Macular Translocation Surgery
    • 7.3.3. Photodynamic Therapy
    • 7.3.4. Vitrectomy

8. Age-related Macular Degeneration Market, by Delivery Method

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Intravitreal implants
  • 8.4. Oral

9. Age-related Macular Degeneration Market, by Healthcare Setting

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmology Clinics

10. Age-related Macular Degeneration Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Age-related Macular Degeneration Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Age-related Macular Degeneration Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Age-related Macular Degeneration Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Genentech relaunches Susvimo for wet AMD with improved vision
    • 14.3.2. Stealth BioTherapeutics launches phase 3 trial for elamipretide to combat dry age-related macular degeneration and improve patient outcomes
    • 14.3.3. LambdaVision secures funding to advance preclinical trials of innovative artificial retina
    • 14.3.4. Science Corporation acquires Pixium Vision's PRIMA retinal implant to enhance vision restoration for AMD patients
    • 14.3.5. Researchers at HKUMed develop groundbreaking photoactivatable nanomedicine for safer and more effective age-related macular degeneration treatment
    • 14.3.6. EyeBio secures USD 130 million Series A funding to advance Restoret therapy for age-related macular degeneration treatment
    • 14.3.7. Astellas Pharma unveils treatment for age-related macular degeneration with promising efficacy and safety results
    • 14.3.8. FDA provides clearance of clinical trials for Aviceda Therapeutics' AVD-104 targeting age-related macular degeneration
    • 14.3.9. Retinal Degeneration Fund's major investment boosts biotech to advance age-related macular degeneration treatments and improve quality of life
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. F. Hoffmann-La Roche Ltd.
    • 14.4.2. Novartis AG
    • 14.4.3. Bayer AG
    • 14.4.4. Astellas Pharma Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adverum Biotechnologies, Inc.
  • 3. Alkeus Pharmaceuticals, Inc.
  • 4. Allegro Ophthalmics, LLC
  • 5. Amgen Inc.
  • 6. Annexon, Inc.
  • 7. Apellis Pharmaceuticals, Inc.
  • 8. AsclepiX Therapeutics
  • 9. Astellas Pharma Inc.
  • 10. Bausch Health Companies Inc.
  • 11. Bayer AG
  • 12. Biocon Ltd
  • 13. Biogen Inc.
  • 14. Clearside Biomedical, Inc.
  • 15. EyePoint Pharmaceuticals, Inc.
  • 16. F. Hoffmann-La Roche Ltd.
  • 17. Formycon AG
  • 18. Grifols, S.A.
  • 19. Ionis Pharmaceuticals, Inc.
  • 20. Johnson & Johnson Services, Inc.
  • 21. Kodiak Sciences Inc.
  • 22. Lineage Cell Therapeutics, Inc.
  • 23. Lupin Limited
  • 24. Merck & Co., Inc.
  • 25. Nicox S.A.
  • 26. Novartis AG
  • 27. PanOptica, Inc.
  • 28. Pfizer Inc.
  • 29. Regeneron Pharmaceuticals, Inc.
  • 30. Sandoz Group AG
  • 31. Sun Pharmaceutical Industries, Ltd.
  • 32. Teva Pharmaceutical Industries Ltd.
  • 33. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-CURRENCY
  • FIGURE 2. AGE-RELATED MACULAR DEGENERATION MARKET MULTI-LANGUAGE
  • FIGURE 3. AGE-RELATED MACULAR DEGENERATION MARKET RESEARCH PROCESS
  • FIGURE 4. AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. AGE-RELATED MACULAR DEGENERATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. AGE-RELATED MACULAR DEGENERATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AGE-RELATED MACULAR DEGENERATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AGE-RELATED MACULAR DEGENERATION MARKET DYNAMICS
  • TABLE 7. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTI-VEGF AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ANTIOXIDANTS & SUPPLEMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY GENE THERAPY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY MACULAR TRANSLOCATION SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY VITRECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY INTRAVITREAL IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 179. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 207. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 228. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 249. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 263. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 270. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY HEALTHCARE SETTING, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 291. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY PHARMACEUTICALS, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY SURGICAL INTERVENTIONS, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN AGE-RELATED MACULAR DEGENERATION MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN AGE-RELATED MACULAR DEGENERATION